Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock ...

The National Agency for Food and Drug Administration and Control, NAFDAC, has alerted Nigerians, including healthcare ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has notified Nigerians, including healthcare ...

Patients treating breast cancer face the risk of purchasing a fake version of Phesgo 600mg injectable solution ...

NAFDAC has warned of a counterfeit Phesgo 600mg/600mg/10ml cancer drug batch, confirming fake labels, tampering, and an invalid batch number.

NAFDAC has alerted healthcare providers and the public about a suspected counterfeit batch of Phesgo 600mg/600mg/10ml ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

The National Agency for Food and Drug Administration and Control (NAFDAC) warns the public against counterfeit cancer drugs Phesgo® 600mg ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

National Agency for Food and Drugs Administration and Control (NAFDAC) has issued an alert to healthcare providers and the public about a suspected ...

“The Marketing Authorization Holder (MAH) Roche received a complaint from a doctor at Lagos University Teaching Hospital (LUTH-NSIA) reporting a suspected counterfeit Phesgo® 600mg ...